<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of Clinical Practice</journal-id><journal-title-group><journal-title xml:lang="en">Journal of Clinical Practice</journal-title><trans-title-group xml:lang="ru"><trans-title>Клиническая практика</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-3095</issn><issn publication-format="electronic">2618-8627</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">8116</article-id><article-id pub-id-type="doi">10.17816/clinpract7415-20</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">ThE uSE of AbErrAnT METhylATEd gEnES SEPT9 And VIM for clInIcAl dIAgnoSIS of colorEcTAl cAncEr</article-title><trans-title-group xml:lang="ru"><trans-title>ИСПОЛЬЗОВАНИЕ АБЕРРАНТНО МЕТИЛИРОВАННЫХ ГЕНОВ SEPT9 И VIM ДЛЯКЛИНИЧЕСКОЙ ДИАГНОСТИКИ КОЛОРЕКТАЛЬНОГО РАКА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Brovkina</surname><given-names>O I</given-names></name><name xml:lang="ru"><surname>Бровкина</surname><given-names>Ольга Игоревна</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат биологических наук, старший научный сотрудник лаборатории генетики ЦБМТ ФГБУ ФНКЦ ФМБА России</p></bio><email>brov.olia@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gordiev</surname><given-names>M G</given-names></name><name xml:lang="ru"><surname>Гордиев</surname><given-names>Марат Гордиевич</given-names></name></name-alternatives><bio xml:lang="ru"><p>заведующий Молекулярно-диагностической лабораторией ГАУЗ «Республиканский клинический онкологический диспансер МЗ Республики Татарстан»</p></bio><email>marat7925@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khodyrev</surname><given-names>D S</given-names></name><name xml:lang="ru"><surname>Ходырев</surname><given-names>Дмитрий Сергеевич</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат биологических наук, старший научный сотрудник лаборатории генетики ЦБМТ ФГБУ ФНКЦ ФМБА России</p></bio><email>DmKh008@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nikitin</surname><given-names>A G</given-names></name><name xml:lang="ru"><surname>Никитин</surname><given-names>Алексей Георгиевич</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат биологических наук, заведующий лабораторией генетики ЦБМТ ФГБУ ФНКЦ ФМБА России</p></bio><email>avialn@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Averyanov</surname><given-names>A V</given-names></name><name xml:lang="ru"><surname>Аверьянов</surname><given-names>Александр Вячеславович</given-names></name></name-alternatives><bio xml:lang="ru"><p>заведующий отделением пульмонологии ФНКЦ ФМБА России,руководитель Центра биомедицинских технологий, д.м.н.</p></bio><email>averyanovav@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ЦБМТ ФГБУ ФНКЦ ФМБА России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ФГБУ ФНКЦ ФМБА России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2016</year></pub-date><volume>7</volume><issue>4</issue><issue-title xml:lang="en">NO4 (2016)</issue-title><issue-title xml:lang="ru">№4 (2016)</issue-title><fpage>15</fpage><lpage>20</lpage><history><date date-type="received" iso-8601-date="2018-03-05"><day>05</day><month>03</month><year>2018</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Brovkina O.I., Gordiev M.G., Khodyrev D.S., Nikitin A.G., Averyanov A.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, Бровкина О.И., Гордиев М.Г., Ходырев Д.С., Никитин А.Г., Аверьянов А.В.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Brovkina O.I., Gordiev M.G., Khodyrev D.S., Nikitin A.G., Averyanov A.V.</copyright-holder><copyright-holder xml:lang="ru">Бровкина О.И., Гордиев М.Г., Ходырев Д.С., Никитин А.Г., Аверьянов А.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://clinpractice.ru/clinpractice/article/view/8116">https://clinpractice.ru/clinpractice/article/view/8116</self-uri><abstract xml:lang="en"><p>Definition of epigenetic disorders is important for early diagnosis of colorectal cancer. To obtain a model of diagnostic test system with high sensitivity and specificity, we determined the frequency of methylation in SEPT9 and VIM genes. Epigenetic events also were compared with mutations in the RAS family genes. It was confirmed the presence of aberrant methylation in SEPT9 and VIM genes in tumor cells. DNA of tumor samples was significantly more methylated than samples with DNA from adjacent tissue (P = 8,67E-19 for SEPT9 gene and P=8,68E-19 for VIM gene). In the group of patients carried mutations in KRAS or NRAS genes tumor DNA significantly more methylated in gene SEPT9 (P = 0.0018), in contrast to the tumor DNA from patients not carried mutations. We have demonstrated that the combined use of methylation markers can improve the sensitivity of the test systems used in the diagnostics of colon cancer.</p></abstract><trans-abstract xml:lang="ru"><p>Определение эпигенетических нарушений имеет большое значение для ранней диагностики колоректального рака (КРР). Для получения модели диагностической тест-системы с высокими показателями чувствительности и специфичности мы определяли частоту метилирования в генах SEPT9 и VIM. При анализе эпигенетических нарушений нами также учитывались мутации в генах семейства RAS. В нашей работе подтверждается наличие аберрантного метилирования в генах SEPT9 и VIM в клетках опухоли. ДНК образцов опухоли была достоверно чаще метилирована, чем ДНК образцов прилежащей ткани (P =8,67E-19 для гена SEPT9 и P=8,68E-19 для гена VIM). В группе пациентов, имеющих мутации в генах KRAS или NRAS, ДНК опухолевых образцов достоверно чаще метилирована в генe SEPT9 (P=0.0018), в отличие от ДНК опухолевых образцов пациентов, не несущих данных мутаций. Нами было продемонстрировано, что использование совокупности маркеров метилирования позволяет улучшить чувствительность тест- систем, используемых в диагностике КРР.</p></trans-abstract><kwd-group xml:lang="en"><kwd>VIM</kwd><kwd>colorectal cancer</kwd><kwd>aberrant methylation</kwd><kwd>SEPT9</kwd><kwd>VIM genes</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>колоректальный рак</kwd><kwd>аберрантное метилирование</kwd><kwd>гены SEPT9</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Jones P.A., Baylin S.B. 2007. The Epigenomics of Cancer. Cell. 2007;128: 683-692.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Wild N., Andres H., Rollinger W., et al. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res. 2010;16(24):6111-21. doi:10.1158/1078-0432.CCR-10-0119.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37: 646-650.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Russell S.E.H., Hall P.A. Do septins have a role in cancer? Br. J. Cancer. 2005;93: 499-503.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Kinoshita M., Noda M. Roles of septins in the mammalian cytokinesis machinery. Cell Struct Funct. 2001;26: 667-670.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Joo E., Tsang C.W., Trimble W.S. Septins: traffic control at the cytokinesis intersection. Traffic Cph. Den. 2005;6: 626-634.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>McDade S.S., Hall P.A., Russell S.E.H. Translational control of SEPT9 isoforms is perturbed in disease. Hum Mol Genet. 2007;16: 742-752.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Estey M.P., Di Ciano-Oliveira C., Froese C.D., Bejide M.T., Trimble W.S. Distinct roles of septins in cytokinesis: SEPT9 mediates midbody abscission. J Cell Biol. 2010;191: 741-749.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Zou H., Harrington J.J., Shire A.M., et al. Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2686-96.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Brenner D.E., Rennert G. Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst. 2005; 97: 1107-9.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Schneider K.U., Dietrich D., Fleischhacker M., et al. Correlation of SHOX2 Gene Amplification and DNA Methylation in Lung Cancer Tumors. BMC Cancer. 2011 Mar 22;11:102. doi: 10.1186/1471-2407-11-102.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Mikeska T., Craig J.M. DNA Methylation Bio-markers: Cancer and Beyond. Genes. 2014;5:821-864.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Linardou H., Briasoulis E., Dahabreh I.J., et al. 2011. All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat. Rev. 2011;37: 221-233.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Ying H.-Q., Wang F., He B.-S., et al. The involvement of Kras gene 3’-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis. OncoTargets Ther. 2014;7: 1487-1496.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Кит О.И., Водолажский Д.И., Дваденко К.В., et al. 2016. Аберрантное метилирование промоторных участков генов APC, CDH13 и MGMT у больных колоректальным раком. Сибирский Онкологический Журнал. 2016;15: 48-55.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Cerottini J.P., Caplin S., Saraga E., Givel J.C., Benhattar J. The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg. 1998;175: 198-202.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Беляева А.В. Мутации в гене K-RAS у больных колоректальным раком. Автореф. дис. ...канд. мед. наук. Спб.: 2012.- 27 с.</mixed-citation></ref></ref-list></back></article>
